Greater Occipital Nerve Injection Study
| Status: | Completed |
|---|---|
| Conditions: | Migraine Headaches |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/8/2015 |
| Start Date: | June 2013 |
| End Date: | June 2014 |
| Contact: | Kerry S Crawley, BSW |
| Email: | crawley.kerry@mayo.edu |
Ultrasound-guided Greater Occipital Nerve Injection at Novel Proximal Location: A Clinical Series
This study is designed to answer the question of whether injection of the greater occipital
nerve at its proximal origin, near the C2 vertebrae, using ultrasound guidance is effective
in improving pain in human subjects.
HYPOTHESES
1. Ultrasound (US) guided greater occipital nerve (GON) injections are effective at a
novel, proximal C2 location in live, human subjects, measured by improvement in visual
analog scale (VAS) pain scores pre-injection compared to VAS scores 30 minutes
post-injection, 2-weeks post-injection, and 1-month post-injection .
2. Ultrasound (US) guided injection of the greater occipital nerve (GON) at a novel, C2
location is effective at improvement of both occipital neuralgia and cervicogenic
headache demonstrated by improvement in visual analog scale (VAS) pain scores
pre-injection compared to VAS scores 30 minutes post-injection, 2-weeks post-injection,
and 1-month post-injection. We further hypothesize that the mean improvement in VAS
scores at 1-month post injection will be greater than 2 units.
3. Ultrasound (US) guided injection of the greater occipital nerve (GON) at novel,
proximal C2 location in live, human subjects appears safe.
nerve at its proximal origin, near the C2 vertebrae, using ultrasound guidance is effective
in improving pain in human subjects.
HYPOTHESES
1. Ultrasound (US) guided greater occipital nerve (GON) injections are effective at a
novel, proximal C2 location in live, human subjects, measured by improvement in visual
analog scale (VAS) pain scores pre-injection compared to VAS scores 30 minutes
post-injection, 2-weeks post-injection, and 1-month post-injection .
2. Ultrasound (US) guided injection of the greater occipital nerve (GON) at a novel, C2
location is effective at improvement of both occipital neuralgia and cervicogenic
headache demonstrated by improvement in visual analog scale (VAS) pain scores
pre-injection compared to VAS scores 30 minutes post-injection, 2-weeks post-injection,
and 1-month post-injection. We further hypothesize that the mean improvement in VAS
scores at 1-month post injection will be greater than 2 units.
3. Ultrasound (US) guided injection of the greater occipital nerve (GON) at novel,
proximal C2 location in live, human subjects appears safe.
Patients must be referred to Pain Clinic for occipital nerve injection.
Patients are responsible for all clinical costs associated with the injection.
There is no remuneration offered for participation in this study.
Patients are responsible for all clinical costs associated with the injection.
There is no remuneration offered for participation in this study.
Inclusion Criteria:
Subjects must be referred to the Pain Clinic for an occipital nerve injection.
- Must have Occipital Neuralgia and/or Cervicogenic Headache
Exclusion Criteria:
- Bilateral GON symptoms and/or cervicogenic headache symptoms
- History of cervical spine surgery/procedure or trauma in past 6 months that may have
caused or contributed to the occipital pain or cervicogenic headache, excluding
Occipital Nerve Blocks (ONB).
- Evidence of impaired sensation in the GON dermatome region
- Evidence of cranial defect/abnormality near target injection site
- Untreated cutaneous infection, systemic illness, or immunocompromised state
- History of bleeding tendency or use of anticoagulants
- History of adverse reaction to anesthetic agents or corticosteroids
- Occipital nerve block in past 3 months
We found this trial at
1
site
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
